Ease of Administration & Pharmacokinetics

An easy-to-use formulation

Low Viscosity Allows for Easy Injectability and Flexible Subcutaneous Administration1-3

  • Low mean viscosity: 11.6 (± 0.6 )—Lower than 20% IgG products
  • Progressive infusion speed
    • First 6 infusions: 15-20 mL/hour/site
    • Subsequent infusions: 25 mL/hour/site (as tolerated)
    • Maximum: up to 100 mL/hour/ all sites combined (as tolerated)

Find out more about cutaquig administration.

Favorable pharmacokinetics1,2,4

Cutaquig serum IgG trough levels were constant during the study with trough levels around 23% higher under SCIg treatment than prior IVIg treatment.

Higher Trough Levels

There were no patients with IgG trough levels
below 5 g/L for both IVIg and SCIg.1

Learn about cutaquig manufacturing and pathogen safety.

Learn More

  1. Kobayashi RH, Gupta S, Melamed I, et al. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (octanorm [cutaquig®]) in the Treatment of Patients with Primary Immunodeficiencies. Front Immunol. February 2019 | Volume 10 | Article 40.
  2. Cutaquig® (Immune Globulin Subcutaneous (Human) – hipp), 16.5% solution. Full Prescribing Information. Octapharma USA, December 2019.
  3. Gelbmann N, Zöchling A, Mersich C et al. Cutaquig, Immunoglobulin (human) subcutaneous 16.5% solution for injection (165 mg/mL) – biochemical characterization, pathogen safety and stability. Presented at: 2018 Annual Meeting of the Clinical Immunology Society; Toronto, Canada. Poster Presentation.
  4. Octapharma, Data on File.